OAd-tAIB-Luc-mediated luciferase expression levels were significantly attenuated by pre-injection of the low- and high-dose of mouse anti-Ad5 serum, compared to those in the naïve serum-injected groups, at 3 days after OAd administration (Fig. 3B,C), indicating that pre-existing anti-Ad5 neutralizing antibodies attenuated OAd-mediated in vivo transgene expression in the tumor at an early time point. The gene discussed is PSEN2; the disease is neoplasm.